In this sense, high TGFB1 expression in HCC patients, concomitant with high expression of the genes that mediate its invasive effects, such as PDGF, CXCR4, or CD44, (167, 177, 228) would anticipate a benefit for the use of Galunisertib. This evidence concerns the gene CD44 and hepatocellular carcinoma.